Shanghai continues to solidify its role as a global hub for foreign investment, recently certifying 30 new multinational regional headquarters and 15 foreign-funded research and development centers. One such example is Carbogen Amcis (Shanghai) Co Ltd.

Carbogen Amcis, a Switzerland-based biopharmaceutical company specializing in the R&D of small molecules and bioconjugate innovative medicines, has established its sole R&D center in China at Shanghai Chemical Industry Park.

The company's leadership lauds Shanghai as a global innovation hub, highlighting its rich pool of high-tech talent and robust industrial ecosystem as key drivers for attracting foreign investment. Establishing an R&D center in the city enables Carbogen Amcis to collaborate with clients from the early lab-scale phase, thus reducing commercial risks.

The company has also benefited from strong policy support from both municipal authorities and Shanghai Chemical Industry Park. Recently, it obtained a domestic medicine manufacturing license and is in the process of building a GMP-compliant kilogram-scale laboratory for the small-scale production of high-potency medicines.

To date, Shanghai Chemical Industry Park has seen three of its in-house enterprises recognized as foreign-funded R&D centers. Looking ahead, the park is committed to strengthening the competitiveness of local enterprises by creating a first-class business environment and enhancing industrial and talent support policies.

Source: Shanghai Chemical Industry Park